Press Releases

Press Releases

Keyword Search

Oct 28, 2019

CRISPR Therapeutics Provides Business Update and Reports Third Quarter 2019 Financial Results

Oct 21, 2019

CRISPR Therapeutics and Bayer Announce an Update on Casebia Therapeutics

Oct 15, 2019

CRISPR Therapeutics and KSQ Therapeutics Announce License Agreement to Advance Companies’ Respective Cell Therapy Programs in Oncology

Oct 01, 2019

CRISPR Therapeutics to Present at Upcoming Investor Conferences

Sep 17, 2019

CRISPR Therapeutics and ViaCyte Present Positive In Vitro Data Towards a Potential Immune-Evasive Cell Replacement Therapy for Diabetes at EASD 2019

Jul 31, 2019

CRISPR Therapeutics to Present at Upcoming Investor Conferences

Jul 29, 2019

CRISPR Therapeutics Provides Business Update and Reports Second Quarter 2019 Financial Results

Jul 01, 2019

CRISPR Therapeutics Announces Oral Presentation at the 55th Annual Meeting of the European Association for the Study of Diabetes

Jun 06, 2019

Vertex Expands into New Disease Areas and Enhances Gene Editing Capabilities Through Expanded Collaboration with CRISPR Therapeutics and Acquisition of Exonics Therapeutics

May 29, 2019

CRISPR Therapeutics to Present at Upcoming Investor Conferences

May 01, 2019

CRISPR Therapeutics to Participate in Upcoming Investor Conferences

Apr 29, 2019

CRISPR Therapeutics Provides Business Update and Reports First Quarter 2019 Financial Results

Apr 16, 2019

CRISPR Therapeutics and Vertex Announce FDA Fast Track Designation for CTX001 for the Treatment of Beta Thalassemia

Apr 01, 2019

CRISPR Therapeutics to Participate in Upcoming Investor Conferences

Mar 06, 2019

CRISPR Therapeutics to Participate in Upcoming Investor Conferences

Feb 27, 2019

CRISPR Therapeutics Announces Presentations at the American Association for Cancer Research 2019 Annual Meeting

Feb 25, 2019

CRISPR Therapeutics Provides Business Update and Reports Fourth Quarter and Full Year 2018 Financial Results

Feb 25, 2019

CRISPR Therapeutics and Vertex Announce Progress in Clinical Development Programs for the Investigational CRISPR/Cas9 Gene-Editing Therapy CTX001

Feb 21, 2019

CRISPR Therapeutics Proposes New Members to the Board of Directors

Feb 19, 2019

CRISPR Therapeutics and StrideBio Expand Exclusive Development and Option Agreement

Jan 22, 2019

CRISPR Therapeutics and ProBioGen Sign Collaboration and License Agreement to Develop Novel In Vivo Delivery Technologies

Jan 04, 2019

CRISPR Therapeutics and Vertex Announce FDA Fast Track Designation for CTX001 for the Treatment of Sickle Cell Disease